In this webinar, you will learn: How mAb irreproducibility could unknowingly impact your research outcomes Proven strategies to mitigate reproducibility risks when using research reagents The role of antibody sequencing in ensuring reproducibility with mAbs Rapid, cost-effective sequence confirmation for routine applications The next frontier: polyclonal antibody sequencing and recombinant pAbs [...]
This paper is now published in Nature Communications! Le Bihan, T., Nunez de Villavicencio Diaz, T., Reitzel, C. et al. De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination. Nat Commun 15, 8790 (2024). https://doi.org/10.1038/s41467-024-53105-8 In this webinar, you will: Explore how using a [...]
In this webinar, you will learn: How AI and HDX-MS are applied in screening, epitope mapping, and selecting neutralizing antibodies against SARS-Cov-2. The predictive capabilities of AI computational modeling and its validation and refinement by high-resolution HDX-MS. How the integration of AI with HDX-MS informs antibody characterization for the accelerated development of therapeutic [...]
In this webinar, you will… Learn the details of LC-MS based antibody characterization in early discovery and production pipelines Explore in-depth the analytical methodologies and strategies essential for comprehensive antibody characterization, covering post-translational modifications, glycan profiles, peptide mapping, and disulfide linkages Ask your burning questions and get expert guidance on navigating antibody [...]
In this webinar, you will learn: Non-Invasive Liquid Biopsies: Cell-free DNA as a key analyte for non-invasive liquid biopsies for cancer diagnosis and monitoring. Enhanced Cell-Free DNA Recovery: Strategies to improve cell-free DNA recovery, including the use of DNA priming agents like DNA-binding monoclonal antibodies. Fc-Domain Engineering: The process of engineering [...]
In this webinar, you will learn: Workflows for antibody characterization that extend beyond the primary amino acid sequence How to leverage HDX-MS for epitope mapping and SPR for binding kinetics to understand the mechanism of action and maximize the effectiveness of your characterization efforts How to ensure high-quality antibody production with [...]
In this webinar, you will learn: Antibody technologies for the design of unique antibody formats Advancements in engineering efforts for the development of functionally tailored antibodies, recombinant isotype antibody panels, and multivalent fragment antibody constructs Characterization of different bispecific antibody formats Next generation protein sequencing to aid in bispecific antibody design [...]
In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]
In this webinar, you will learn: A strategy for generating recombinant mAbs and antibody derivatives directed towards antigens involved in mitotic cell division Methods for antibody engineering and customization, species switching, and construction of antibody fragments How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid engineering and recombinant production of [...]
In this webinar, you will learn: IVD and immunoassays, supply chain risk management considerations How monoclonal and polyclonal antibody sequencing works, requirements Effective production, validation, and scale-up of recombinant antibody reagents Characterization of mAbs for assay design Abstract Polyclonal antibodies (pAbs) are well known for their robustness and [...]
In This Webinar, You Will Learn: Why IP is important in the development of antibody-based assets Patent application process and requirements How to strengthen patent applications Applications of De Novo Protein Sequencing, SPR assays, and HDX-MS for antibody-related patent applications Abstract In the development of novel and innovative antibody-based assets, [...]
In this webinar, you will learn: How Rapid Novor’s de novo polyclonal sequencing platform REpAb® can accelerate any nanobody development pipeline How SPR and HDX-MS integrate into an antibody discovery and development workflow How to choose optimal lead candidates with SPR and HDX-MS How epitopes can be characterized using SPR and HDX-MS [...]
In this SPR webinar, you will learn: How SPR works and its unique advantages for kinetic analysis of antibody-antigen interactions Applications of SPR in antibody discovery Functionality of SPR in antibody characterization Abstract Due to their ability to bind biomolecules specifically and tightly, antibodies are highly sought [...]
Webinar Highlights You will learn: Introduction to the structure and function of the tuberous sclerosis protein complex (pTSC) A novel strategy for isolating and purifying protein complexes from native sources using recombinantly produced Fabs How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid design and engineering of recombinant antibody [...]
As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. By comparing the antibody response towards specific wild-type influenza strains and COBRA antigens, we can begin to understand the potential for COBRA-based vaccines to be used in the clinic.
Known, high-performing and well used antibodies against useful targets on CAR-T cells can be examined for mechanism of action using proteomics and mass spectrometry. Knowledge of the antibody sequences via Next Generation Protein Sequencing (NGPS) can be useful for humanizing or otherwise engineering constructs. Rapid Epitope mapping by HDX can be useful for both epitope and paratope engineering strategies.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Research Challenges in Veterinary Medicine Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Non-invasive, sensitive, accurate, and easy-to-manufacture IVDs will be critical to detect and monitor diseases where misfolded proteins play a significant role such as neurological illnesses like Alzheimer’s, cancers like multiple myeloma, among others.
There have been cases where researchers have trusted a kit, and they see a positive reaction only to, unfortunately, realize that the kit was actually detecting another protein because the kit’s antibody lot changed. Such was the case for the University of Toronto’s Diamandis team who spent half a million dollars and nearly two years due to an unreliable antibody. A certificate proving that the protein sequence of an antibody remains unchanged would have easily avoided the aforementioned mishaps.
Polyclonal antibodies are popular research reagents for their high sensitivity and robust cross-platform performance. But few companies consider them viable for therapeutic applications as they are almost impossible to characterize. Additionally, they suffer from a lack of reproducibility and limited supply. Monoclonal antibodies (mAbs) can be reliably characterized and produced for therapeutic applications, but are more costly to discover and develop. Rapid Novor’s REpAb technology can overcome these limitations by capturing the sequences of the most abundant IgG in a pAb and enabling indefinite antibody production. Here we report the first successful conversion of a goat polyclonal antibody into a cocktail of recombinant mAbs using only the pAb protein sample.
Over the past several years Rapid Novor has been developing the world's best antibody protein sequencing platform, with over 2700 monoclonal antibodies and proteins sequenced. In 2020, they unveiled their most advanced technology to date- REpAb® polyclonal antibody sequencing. The platform combines the world's best protein sequencing technology and NGS to comprehensively mine the antigen specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patient's blood.
Our team, along with four other industry panelists, discuss ways to safeguard their research through recombinant antibodies, cell culturing procedures, antibody protein sequences, and reference identifiers.
Of interest to human and veterinary drug development scientists, biologics and biosimilars development scientists, scientists performing pre-clinical assay development, immunotherapy researchers, oncolytic therapy development scientists, gene therapy development scientists, gene therapy, and oncolytic therapy researchers, CAR-T, and CAR-NK development scientists
This webinar offers insight into how DNA and protein sequencing compare to each other.
Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®. After successfully launching their proteogenomics based sequencing technology to deconvolute the immune response, the team has further evolved the technology and has derived the most abundant mAb sequences directly from rabbit blood using only proteomics. The talk will surround the development, progress and use cases for REpAb®.
Other than a paucity in widespread use, such efforts still do not address the main issue: the uniqueness of antibodies. Unlike currency, antibodies are non-fungible. To manufacture a replica of a specific antibody, we must first know its sequence. Sometimes, scientists may obtain the sequence through nucleotide sequencing means.
Over the past several years Rapid Novor has been developing the world’s best antibody protein sequencing platform, sequencing over 2700 monoclonal antibodies and proteins. In 2020, they unveiled their most advanced technology to date - REpAb® polyclonal antibody sequencing. The platform combines the world’s best protein sequencing technology and NGS to comprehensively mine the antigen-specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patients’ blood.
When it comes to polyclonal antibodies, how they are discovered can be just as important as how they are reproduced. In our talk originally presented at Antibody Engineering & Therapeutics Digital 2021, we highlighted the latest technology that’s capable of capturing the most abundant and high-affinity monoclonal antibodies directly from a poly mixture.
At PepTalk 2021, we discussed the importance of antibody standardization and explained why it’s crucial for the longevity of your research. You can listen to the full on-demand video here.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
If you could have guaranteed stability, certainty, and reproducibility for your research, would you be interested? Imagine this, if you’re 2 years into your project and your freezer died along with all of your important cell lines, what would you do? This is just one of the situations covered in this webinar, along with many other solutions researchers have begun to implement to safeguard their efforts. Whether you’re looking to proceed with stability and certainty or you’re looking for an immediate solution for your current reproducibility challenges, protein sequencing may be the answer.
Our team has perfected the art of monoclonal antibody sequencing and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony will walk through our new polyclonal sequencing platform that uses both proteomics and genomics to sequence the most abundant antibodies found in polyclonal sera.
In this on-demand webinar, our scientific sales executive Jennifer, will briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein sequencing into their pipelines, and discuss how Rapid Novor is able to routinely and robustly achieve 100% accuracy and 100% coverage for both monoclonal and oligoclonal antibodies.
In this on-demand webinar, we discuss why it is important to characterize antibodies based on their physical properties not just by what they bind, and how you can easily do the former via mass spectrometry-based protein sequencing.